Is Renal Infarction Linked to Cardiac Amyloidosis? Is Renal Infarction Linked to Cardiac Amyloidosis?
First study of its kind finds renal infarction in cardiac amyloidosis may be more common than previously thought, especially in patients with acute kidney injury, but an expert questions the results.Medscape Medical News (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - June 4, 2019 Category: Transplant Surgery Tags: Nephrology News Source Type: news
AI+AR Equals Altoida ’s Alzheimer’s Detection Solution
Altoida is combining artificial intelligence, machine learning, and augmented reality to help detect Alzheimer’s disease. The Houston, TX-based company has struck a chord with venture capitalists, raising $6.3 million in a series A round.
The financing was led by M Ventures, the corporate venture capital arm of the science and technology company Merck KGaA, Darmstadt, Germany, with participation from Grey Sky Venture Partners, VI Partners AG, Alpana Ventures, and FYRFLY Venture Partners.
The new capital will be used to further expand Altoida's presence worldwide with an immediate focus on commercializati...
Source: MDDI - May 31, 2019 Category: Medical Devices Authors: Omar Ford Tags: Assembly and Automation Source Type: news
Renal infarction is associated with acute kidney injury in patients with cardiac amyloidosis
(Elsevier) Systemic amyloidosis is a major cause of renal injury, mostly due to direct kidney damage caused by deposits of abnormal protein called amyloid, in the kidney parenchyma. In patients with cardiac amyloidosis, renal infarction is associated with acute kidney injury according to a new study in Mayo Clinic Proceedings, published by Elsevier. Investigators recommend that a diagnosis of renal infarction should be systematically considered in patients with unexplained acute kidney injury in the context of cardiac amyloidosis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 15, 2019 Category: International Medicine & Public Health Source Type: news
FDA Approves New Treatments Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) for Heart Disease Caused by Transthyretin Mediated Amyloidosis
May 06, 2019 -- On May 3, the U.S. Food and Drug Administration approved Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules for the treatment of the heart disease (cardiomyopathy) caused by transthyretin mediated amyloidosis (ATTR-CM)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 6, 2019 Category: Drugs & Pharmacology Source Type: news
FDA Approves Treatments for Heart Failure Caused by Rare Disease
MONDAY, May 6, 2019 -- Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules have been approved to treat adults with cardiomyopathy caused by transthyretin mediated amyloidosis (ATTR-CM), the U.S. Food and Drug Administration announced... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 6, 2019 Category: Pharmaceuticals Source Type: news
Two Drugs Approved for Cardiomyopathy Caused by Amyloidosis
Two different versions of tafamadis get the FDA ’s nod to treat a rare heart disease. (Source: ConsultantLive)
Source: ConsultantLive - May 6, 2019 Category: Internal Medicine Authors: Valerie DeBenedette Tags: Cardiology Cardiovascular Diseases Heart Health Latest e-News New Products The Latest Source Type: news
FDA OKs Two Tafamidis Formulations for Rare Cardiomyopathy FDA OKs Two Tafamidis Formulations for Rare Cardiomyopathy
These are the first FDA-approved treatments for transthyretin-mediated amyloidosis cardiomyopathy, a rare and often fatal disease caused by deposition of amyloid fibrils in the myocardium.FDA Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 6, 2019 Category: Cardiology Tags: Cardiology News Alert Source Type: news
FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis
On May 3, the U.S. Food and Drug Administration approved Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules for the treatment of the heart disease (cardiomyopathy) caused by transthyretin mediated amyloidosis (ATTR-CM) in adults. These are the first FDA-approved treatments for ATTR-CM. Vyndaqel and Vyndamax have the same active moiety, tafamidis, but they are not substitutable on a milligram to milligram basis and their recommended doses differ. (Source: World Pharma News)
Source: World Pharma News - May 6, 2019 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news
Molecules that prevent protein misfolding point to new type of therapy for AL amyloidosis
(Scripps Research Institute) Scientists at Scripps Research have identified a group of small molecules that prevent structural changes to proteins that are at the root of AL amyloidosis, a progressive and often fatal disease. The drug mechanism that the team identified is analogous to a different drug that also originated at Scripps Research: Tafamidis, which stabilizes the protein transthyretin to treat the most common systemic amyloid disease that affects the heart or other organs. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 11, 2019 Category: Cancer & Oncology Source Type: news
Molecules that curb errant proteins of AL amyloidosis point to new type of therapy
(Scripps Research Institute) Scientists at Scripps Research have identified a group of small molecules that prevent structural changes to proteins that are at the root of AL amyloidosis, a progressive and often fatal disease. The drug mechanism that the team identified is analogous to a different drug that also originated at Scripps Research: Tafamidis, which stabilizes the protein transthyretin to treat the most common systemic amyloid disease that affects the heart or other organs. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 11, 2019 Category: Cancer & Oncology Source Type: news
On Rare Disease Day, Alnylam launches patient advocacy grant program
In honor of Rare Disease Day, Alnylam Pharmaceuticals has launched a grant program for patients advocacy groups increasing awareness of two uncommon diseases.
Alnylam (Nasdaq: ALNY) announced the first seven recipients of its new Advocacy for Impact Grants program Thursday. Through the program, the drug company will give out $248,000 to organizations focused on the rare diseases acute hepatic porphyria and ATTR amyloidosis.
The activities of those grou ps include advocating for better diagnosis… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 28, 2019 Category: Pharmaceuticals Authors: Allison DeAngelis Source Type: news
C2N Launches Trial for Alzheimer ’s Detection Test
C2N Diagnostics is experiencing a couple of breakthroughs with its Alzheimer’s disease detection test - one courtesy of FDA. The agency, which is slowly rising back to full strength after the temporary government shutdown, granted the St. Louis-based company breakthrough device designation for a brain amyloidosis blood test.
In addition, C2N said it is launching its Plasma Test for Amyloid Risk Screening (PARIS) Study that is evaluating and validating the clinical diagnostic performance of the C2N brain amyloidosis blood test.
The company said the C2N test is a blood-based in vitro diagnostic being develo...
Source: MDDI - January 29, 2019 Category: Medical Devices Authors: Omar Ford Tags: IVD Source Type: news
Kidney Transplant May Be Appropriate for Some With AL Amyloidosis Kidney Transplant May Be Appropriate for Some With AL Amyloidosis
In selected patients with light chain (AL) amyloidosis who are reaching end-stage renal disease (ESRD), kidney transplantation is a worthwhile approach, according to Boston-based researchers.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - January 12, 2019 Category: Surgery Tags: Nephrology News Source Type: news
Quiz: Multiple Myeloma Patients With AL Amyloidosis
Challenge yourself with our latest quiz covering management of AL amyloidosis in the treatment of patients with multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - December 10, 2018 Category: Cancer & Oncology Source Type: news
Localized Ureteral Amyloidosis Mimicking Urothelial Carcinoma Localized Ureteral Amyloidosis Mimicking Urothelial Carcinoma
How was the unusual origin of this patient ' s left-sided flank pain determined?Applied Radiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 12, 2018 Category: Consumer Health News Tags: Radiology Journal Article Source Type: news
